ClinicalTrials.gg
CompletedNCT01333501CognitionUpdated Mar 21, 2017Results posted

Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms

A Phase 4 interventional study of Fingolimod and Interferon beta 1b in Multiple Sclerosis, sponsored by Novartis Pharmaceuticals. Completed at 26 sites in 2 countries. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2017-03-21.

Primary conditionMultiple Sclerosis, Relapsing-RemittingRegistry: Multiple SclerosisReclassifiedWhy we changed it
Registry
Multiple Sclerosis — the first condition term the registry derived for this study.
ClinicalTrials.gg
Multiple Sclerosis, Relapsing-Remitting
Why
  1. The study's title name Multiple Sclerosis, Relapsing-Remitting, a narrower term within Multiple Sclerosis.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
151
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 19 studies testing fingolimod in Multiple Sclerosis, Relapsing-Remitting — none open to participants now, 1 under way, none of them phase 3. fingolimod · Multiple Sclerosis, Relapsing-Remitting.

Enrollment
9th of 19
151 · median 142
Started
2011
with 5 others
Phase 4
14 of 19
none open now
Registered
5th of 19
by date
Lead sponsor
14 of 19
Novartis Pharmaceuticals

Among the 19 studies testing fingolimod in Multiple Sclerosis, Relapsing-Remitting, this one is the 9th largest by enrollment, is one of 6 that started in 2011, is one of 14 in phase 4, and was the 5th registered.

Multiple Sclerosis, Relapsing-Remitting

618 studies on the registry are indexed under Multiple Sclerosis, Relapsing-Remitting; 83 are open to participants now.

Browse Multiple Sclerosis, Relapsing-Remitting studies →

Open to participants now

None of the 19 studies testing fingolimod in Multiple Sclerosis, Relapsing-Remitting is open now. The open studies under Multiple Sclerosis, Relapsing-Remitting, anywhere →

About fingolimod

fingolimod: first FDA approval 2010 (GILENYA), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 60 Multiple Sclerosis, Relapsing-Remitting studies recruiting now, 11 (18%) set no upper age limit and 43 (72%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 50 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 19 studies testing fingolimod in Multiple Sclerosis, Relapsing-Remitting as a file.
02

Study summary

The purpose of this pilot study is to evaluate, by means of a specific cognitive test battery (Brief Repeatable Battery and Delis-Kaplan Executive Function System scale), the slowing/reduction of cognitive dysfunction progression in RRMS patients after 18 months of treatment with fingolimod in comparison with interferon beta 1b treatment, and to evaluate which test of the battery is the most sensitive in detecting differences between treatment groups.

03

Conditions studied

  • Multiple Sclerosis

Keywords

  • Multiple sclerosis
  • cognitive symptoms
  • relapsing-remitting multiple sclerosis (RRMS)
  • fingolimod
  • Magnetic resonance imaging (MRI)
04

In context

Multiple Sclerosis, Relapsing-Remitting Reclassified

618 studies on the registry are indexed under Multiple Sclerosis, Relapsing-Remitting; 83 are open to participants now.

This study's enrollment of 151 is above the median of 66 across 437 interventional studies indexed under Multiple Sclerosis, Relapsing-Remitting.

Browse Multiple Sclerosis, Relapsing-Remitting studies →

Lead sponsor

Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.

Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.

Compared within Multiple Sclerosis, Relapsing-Remitting, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Multiple Sclerosis. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with relapsing-remitting forms of MS defined by 2005 revised McDonald criteria.
  • Patients with active disease, defined as at least one clinical relapse in the last year, or two clinical relapses in the last two years if there are signs of disease activity at one brain MRI scan performed in the last six months.
  • Patients with cognitive impairment at screening, defined as at least one test of the Rao's Brief Repeatable Battery with scores falling outside the 90th percentile of the normative data.

Exclusion criteria

Exclusion Criteria:

  • Patients who had already been treated with multiweekly interferon (interferon beta 1b, or beta 1a multiweekly) and had an unsatisfactory response according to the judgment of the investigator.
  • Patients with hyperactive forms of the MS disease according to the judgment of the investigator.
  • Patients with an EDSS score higher than 5.
  • Patients with a prior or current diagnosis of Major Depression according to .
  • Patients with a history of chronic disease of the immune system other than MS such as known immunodeficiency syndrome.

Other protocol-defined inclusion/exclusion criteria may apply

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

06

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
151 participants (actual)

Study arms

  • Experimental
    Fingolimod

    0.5 mg in capsules for oral administration once daily

    Drug: Fingolimod

  • Active comparator
    Interferon beta 1b

    250 μg injected s.c. every other day

    Drug: Interferon beta 1b

Interventions

07

What researchers measure

Primary outcomes

  1. Change From Screening in Selective Reminding Test - Long-Term Storage (SRT-LTS) Raw Score

    Brief Repeatable Battery (BRB)- widely used as a clinical and research tool, with 68% sensitivity and 85% specificity. It consists of the serial administration of 5 tests. One of the tests is SRT (Selective Reminding Test) for episodic memory (verbal learning and delayed recall). A word recalled on two consecutive trials is considered to have entered long-term storage (LTS) on the first of these trials and scored as LTS on all following trials. The total of the words in LTS of all six trials is then summed. The total score ranged from 0 to 72. Higher values represent a better outcome.

    Time frame: Screening (-1month), 18 month

  2. Change From Screening in Selective Reminding Test - Consistent Long Term Retrieval (SRT-CLTR) Raw Score

    Brief Repeatable Battery (BRB)- widely used as a clinical and research tool, with 68% sensitivity and 85% specificity. It consists of the serial administration of 5 tests. One of the tests is SRT (Selective Reminding Test) for episodic memory (verbal learning and delayed recall). A word recalled on two consecutive trials is considered to have entered long-term storage (LTS) on the first of these trials and scored as LTS on all following trials. The total of the words in LTS of all six trials is then summed. If a word in LTS is consistently recalled on all subsequent trials, it is then scored as Consistent Long Term Retrieval (CLTR). The total of the words in CLTR of all six trials is summed. The total score ranged from 0 to 72. Higher values represent a better outcome.

    Time frame: Screening (-1month), 18 month

  3. Change From Screening in Spatial Recall Test (SPART) Raw Score

    Spatial Recall Test (SPART) for visuospatial learning and delayed recall.Spatial Recall Test (10/36): The spatial recall test assesses visuospatial learning and delayed recall (10/36-D). A checkerboard with ten checkers arranged in a pattern is shown to the subject for ten seconds. The subject is then asked to reproduce the same pattern with ten checkers on an empty checkerboard. The test includes three consecutive trials. The score is the total number of correct responses for the tree trials. The total score ranged from 0 to 30. Higher values represent a better outcome.

    Time frame: Screening (-1month), 18 month

  4. Change From Screening in Symbol Digit Modalities Test (SDMT) Raw Score

    Symbol Digit Modality Test (SDMT) for sustained attention and information processing speed. It presents a series of nine symbols, each of which is paired with a single digit labeled 1-9 in a key at the top of the sheet. The reminder of the page has a pseudo-randomized sequence of symbols, and the patient must respond with the digit associated with each of these as quickly as possible. The score is the number of correct answers in 90 seconds. The total score ranged from 0 to 110. Higher values represent a better outcome.

    Time frame: Screening (-1month), 18 month

  5. Change From Screening in Paced Auditory Serial Addition Test - 3 Seconds (PASAT 3) Raw Score

    Paced Auditory Serial Addition Test (PASAT) for working memory (and sustained attention and information processing speed). The patient hears a series of numbers from recordings that are presented at the rate of one every 3 seconds in the first part of the test (PASAT-3). The patient is asked to add each consecutive digit to the one immediately preceding it. Sixty-one digits are presented for each part, and each part has a maximum of 60 correct answers. The total score ranged from 0 to 60. Higher values represent a better outcome.

    Time frame: Screening (-1month), 18 month

  6. Change From Screening in Paced Auditory Serial Addition Test - 2 (PASAT 2) Raw Score

    Paced Auditory Serial Addition Test (PASAT) for working memory (and sustained attention and information processing speed). The patient hears a series of numbers from recordings that are presented at the rate of one every 2 seconds in the second part of the test (PASAT-2). The patient was asked to add each consecutive digit to the one immediately preceding it. Sixty-one digits are presented for each part, and each part has a maximum of 60 correct answers. The total score ranged from 0 to 60. Higher values represent a better outcome.

    Time frame: Screening (-1month), 18 month

  7. Change From Screening in Selective Reminding Test - Delayed Recall (SRT-D) Raw Score

    The tests SRT (Selective Reminding Test) for episodic memory (verbal learning and delayed recall). The Delayed SRT test is the total number of words recalled after a delayed period. The total score ranged from 0 to 12. Higher values represent a better outcome.

    Time frame: Screening (-1month), 18 month

  8. Change From Screening in Spatial Recall Test - Delayed Recall (SPART-D)

    Spatial Recall Test (SPART) for visuospatial learning and delayed recall.Spatial Recall Test (10/36): The spatial recall test assesses visuospatial learning and delayed recall (10/36-D). A checkerboard with ten checkers arranged in a pattern was shown to the subject for ten seconds. The subject was then asked to reproduce the same pattern with ten checkers on an empty checkerboard. The test includes three consecutive trials. The score was the total number of correct responses for the tree trials. The total score ranged from 0 to 10. Higher values represent a better outcome.

    Time frame: Screening (-1month), 18 month

  9. Change From Screening in Word List Generation (WLG)

    Word List Generation (COWAT/WLG): The COWAT assesses verbal fluency on semantic stimulus by asking the patient to produce as many words as possible belonging to a semantic category. The test assessed the verbal fluency, recorded all the possible correct word that a patients should give in 90 sec. No maximum range is available. Higher values represent a better outcome. The score was the number of correct words. The more words the patient pronounces, the better it is. We can imagine that the minimum value might be zero words, , but it is not a score scale.

    Time frame: Screening (-1month), 18 month

  10. Change From Screening in Delis-Kaplan Executive Function System (DKEFS) Condition 1: Free Sorting, Confirmed Correct Sort- Card Set 1+2

    The Delis-Kaplan Executive Function System - Sorting Test is one of the nine tests presented in the DKEFS manual and explores the patient's executive abilities. It has a standard form (version A, administered at screening and Month-18 visit) and an alternate form (version B, administered at Month-9 visit). The standard form consists of the practice card set, card set 1 and card set 2. The alternate form consists of the same practice card set, card set 3 and card set 4. The DKFES test consisted of two testing procedures: free sorting and sort recognition. In free sorting, six scores were obtained: Confirmed Correct sorts for card sets 1 and 2 (or 3 and 4 for version B), sum of confirmed Correct Sorts. In sort recognition, a description score for card set 1 and 2 (or 3 and 4 for version B) was obtained, as well as the sum of description scores of both sets. The total score ranged from 0 to 16. Higher values represent a better outcome

    Time frame: Screening (-1month), 18 month

  11. Change From Screening in DKEFS Condition 1: Free Sorting, Free Sorting, Description Score, Card Set 1+2

    The Delis-Kaplan Executive Function System - Sorting Test is one of the nine tests presented in the DKEFS manual and explores the patient's executive abilities. It has a standard form (version A, administered at screening and Month-18 visit) and an alternate form (version B, administered at Month-9 visit). The standard form consists of the practice card set, card set 1 and card set 2. The alternate form consists of the same practice card set, card set 3 and card set 4. In free sorting, six scores were obtained: Confirmed Correct sorts for card sets 1 and 2 (or 3 and 4 for version B), sum of confirmed Correct Sorts, Free Sorting Description score for card set 1 and 2 (or 3 and 4 for version B) and sum of Free Sorting Description scores. In sort recognition, a description score for card set 1 and 2 (or 3 and 4 for version B) was obtained, as well as the sum of description scores of both sets. The total score ranged from 0 to 64. Higher values represent a better outcome

    Time frame: Screening (-1month), 18 month

  12. Change From Screening in DKEFS Condition 2: Sort Recognition, Sort Recognition Description Score- Card Set 1+2

    The Delis-Kaplan Executive Function System - Sorting Test is one of the nine tests presented in the DKEFS manual and explores the patient's executive abilities. It has a standard form (version A, administered at screening and Month-18 visit) and an alternate form (version B, administered at Month-9 visit). The standard form consists of the practice card set, card set 1 and card set 2. The alternate form consists of the same practice card set, card set 3 and card set 4. Free sorting and sort recognition. In free sorting, six scores were obtained: Confirmed Correct sorts for card sets 1 and 2 (or 3 and 4 for version B), sum of confirmed Correct Sorts, Free Sorting Description score for card set 1 and 2 (or 3 and 4 for version B) and sum of Free Sorting Description scores. The total score ranged from 0 to 64. Higher values represent a better outcome.

    Time frame: Screening (-1month), 18 month

Secondary outcomes

  1. Change From Screening in the Volume of Total T2 Lesions

    Change in volume of total T2-weighted lesions by visit were summarized. Negative values indicate improvement (reduction in lesion volume) and positive values worsening (increase in lesion volume

    Time frame: Screening (-1 month), 18 months

  2. Change From Screening in Montgomery-Asberg Depression Rating Scale (MADRS)

    MADRS measures the overall severity of depressive symptoms. The MADRS had a 10-item checklist. Items are rated on a scale of 0-6, for a total numeric range of scores from 0 (depressive symptoms absent) to 60 (numerically highest level of depressive symptoms).

    Time frame: Screening (-1month), 18 month

  3. Changes in Quality of Life, by Means of the Multiple Sclerosis Quality of Life (MSQoL-54)

    A 54 question measure covers 12 domains; assesses mental and physical health. The physical health composite score is a weighted average of the physical health scales, such as physical function, health perceptions, and energy. The mental health composite score is a weighted average of the mental health scales, such as overall quality of life, cognitive function, and health distress. Each domain has a range from 0 to 100 where higher means better.

    Time frame: Baseline, 18 months

  4. Changes From Baseline in Fatigue Impact Scale (mFIS, Total Score and Scores of the 3 Individual Domains).

    Modified Fatigue Impact Scale (mFIS) questionnaire is described at each time point to evaluate fatigue by means of usual descriptive statistics. Three domains were also defined: Physical Subscale (sum of items 4, 6, 7, 10, 13, 14, 17, 20, 21 and therefore ranging from 0 to 36), Cognitive Subscale (sum of items 1, 2, 3, 5, 11, 12, 15, 16, 18, 19 and therefore ranging from 0 to 40) and Psychosocial Subscale (sum of items 8, 9 and therefore ranging from 0 to 8). Finally, mFIS - overall score ranged from 0 to 80. The mFIS total score was computed as the sum of scores for each item. Lower values represent a better outcome.

    Time frame: Baseline, 18 months

  5. Change From Screening in the Number of New T2 Lesions

    New T2 lesions at a specific visit were assessed relative to the previous visit scan. The total number of lesions (visit 8 to 18 month) is calculated as the sum of the number of lesions.

    Time frame: Screening (-1month), 18 month

  6. Change From Screening in the Volume of Total T1 Hypointense Lesions

    Volume of hypointense post-gadolinium T1 lesion component was measured by MRI scan. Means were estimated using a Mixed-effect model with repeated measures (MMRM) by-visit interaction.

    Time frame: Screening (-1month), 18 month

  7. Change From Screening in the Number of T1 Gd+ Enhancing Lesions

    Total number of post-baseline Gd-enhanced lesions is calculated as a sum of all Gd-enhanced lesions seen on post-baseline scans per visit. Real (not per slice) lesions are counted in this analysis

    Time frame: Screening (-1month), 18 month

  8. Change From Screening in the Percentage of Brain Volume Change

    Calculations of brain volume change were performed using the structural image evaluation of normalized atrophy (SIENA), software included in the Functional Magnetic Resonance Imaging of the Brain (FMRIB) software library. SIENA is a fully automated method for estimating temporal brain volume change.

    Time frame: Screening (-1month), 18 month

  9. Changes in the Environmental Status Scale Score (ESS)

    The Environmental Status Scale (ESS) is used to quickly evaluate a patient for handicap. It was derived from a measure of socio-economic status. It consists of seven parameters: (1) actual work status, (2) financial and economic status, (3) personal residence or home, (4) personal assistance required, (5) transportation, (6) community services, (7) social activity. Each parameter has a single score from minimum 0 to maximum 5. ESS score is the sum of the points for all 7 parameters: minimum score: 0; maximum score: 35. The higher the score the greater the handicap

    Time frame: Baseline, 18 month

08

Results

Posted Mar 21, 2017

Participant flow

Participant flow — Overall Study
MilestoneFingolimodInterferon Beta 1b
Started10651
Full analysis set (fas)8028
Safety population10447
Completed9730
Not completed921
Withdrew: Adverse event31
Withdrew: Abnormal laboratory value21
Withdrew: Unsatisfactory therapeutic effect17
Withdrew: Withdrawn consent312

Outcome measures

PrimaryChange From Screening in Selective Reminding Test - Long-Term Storage (SRT-LTS) Raw Score

Brief Repeatable Battery (BRB)- widely used as a clinical and research tool, with 68% sensitivity and 85% specificity. It consists of the serial administration of 5 tests. One of the tests is SRT (Selective Reminding Test) for episodic memory (verbal learning and delayed recall). A word recalled on two consecutive trials is considered to have entered long-term storage (LTS) on the first of these trials and scored as LTS on all following trials. The total of the words in LTS of all six trials is then summed. The total score ranged from 0 to 72. Higher values represent a better outcome.

Time frame:
Screening (-1month), 18 month
Reported as:
Least squares mean · raw score
Change From Screening in Selective Reminding Test - Long-Term Storage (SRT-LTS) Raw Score
raw scoreFingolimodInterferon Beta 1b
Change From Screening in Selective Reminding Test - Long-Term Storage (SRT-LTS) Raw Score6.32 ± 1.334.46 ± 2.28
Statistical analysis
  • Fingolimod vs Interferon Beta 1b · ANCOVA · p = 0.4940 · Mean difference (net): 1.86 · 95% CI -3.51 to 7.23
PrimaryChange From Screening in Selective Reminding Test - Consistent Long Term Retrieval (SRT-CLTR) Raw Score

Brief Repeatable Battery (BRB)- widely used as a clinical and research tool, with 68% sensitivity and 85% specificity. It consists of the serial administration of 5 tests. One of the tests is SRT (Selective Reminding Test) for episodic memory (verbal learning and delayed recall). A word recalled on two consecutive trials is considered to have entered long-term storage (LTS) on the first of these trials and scored as LTS on all following trials. The total of the words in LTS of all six trials is then summed. If a word in LTS is consistently recalled on all subsequent trials, it is then scored as Consistent Long Term Retrieval (CLTR). The total of the words in CLTR of all six trials is summed. The total score ranged from 0 to 72. Higher values represent a better outcome.

Time frame:
Screening (-1month), 18 month
Reported as:
Least squares mean · Raw score
Change From Screening in Selective Reminding Test - Consistent Long Term Retrieval (SRT-CLTR) Raw Score
Raw scoreFingolimodInterferon Beta 1b
Change From Screening in Selective Reminding Test - Consistent Long Term Retrieval (SRT-CLTR) Raw Score5.93 ± 1.493.96 ± 2.56
Statistical analysis
  • Fingolimod vs Interferon Beta 1b · ANCOVA · p = 0.5183 · Mean difference (net): 1.97 · 95% CI -4.06 to 7.99
PrimaryChange From Screening in Spatial Recall Test (SPART) Raw Score

Spatial Recall Test (SPART) for visuospatial learning and delayed recall.Spatial Recall Test (10/36): The spatial recall test assesses visuospatial learning and delayed recall (10/36-D). A checkerboard with ten checkers arranged in a pattern is shown to the subject for ten seconds. The subject is then asked to reproduce the same pattern with ten checkers on an empty checkerboard. The test includes three consecutive trials. The score is the total number of correct responses for the tree trials. The total score ranged from 0 to 30. Higher values represent a better outcome.

Time frame:
Screening (-1month), 18 month
Reported as:
Least squares mean · Raw score
Change From Screening in Spatial Recall Test (SPART) Raw Score
Raw scoreFingolimodInterferon Beta 1b
Change From Screening in Spatial Recall Test (SPART) Raw Score1.46 ± 0.523.06 ± 0.89
Statistical analysis
  • Fingolimod vs Interferon Beta 1b · ANCOVA · p = 0.1334 · Mean difference (net): -1.60 · 95% CI -3.69 to 0.50
PrimaryChange From Screening in Symbol Digit Modalities Test (SDMT) Raw Score

Symbol Digit Modality Test (SDMT) for sustained attention and information processing speed. It presents a series of nine symbols, each of which is paired with a single digit labeled 1-9 in a key at the top of the sheet. The reminder of the page has a pseudo-randomized sequence of symbols, and the patient must respond with the digit associated with each of these as quickly as possible. The score is the number of correct answers in 90 seconds. The total score ranged from 0 to 110. Higher values represent a better outcome.

Time frame:
Screening (-1month), 18 month
Reported as:
Least squares mean · Raw score
Change From Screening in Symbol Digit Modalities Test (SDMT) Raw Score
Raw scoreFingolimodInterferon Beta 1b
Change From Screening in Symbol Digit Modalities Test (SDMT) Raw Score2.19 ± 1.123.93 ± 1.93
Statistical analysis
  • Fingolimod vs Interferon Beta 1b · ANCOVA · p = 0.4501 · Mean difference (net): -1.73 · 95% CI -6.27 to 2.81
PrimaryChange From Screening in Paced Auditory Serial Addition Test - 3 Seconds (PASAT 3) Raw Score

Paced Auditory Serial Addition Test (PASAT) for working memory (and sustained attention and information processing speed). The patient hears a series of numbers from recordings that are presented at the rate of one every 3 seconds in the first part of the test (PASAT-3). The patient is asked to add each consecutive digit to the one immediately preceding it. Sixty-one digits are presented for each part, and each part has a maximum of 60 correct answers. The total score ranged from 0 to 60. Higher values represent a better outcome.

Time frame:
Screening (-1month), 18 month
Reported as:
Least squares mean · Raw score
Change From Screening in Paced Auditory Serial Addition Test - 3 Seconds (PASAT 3) Raw Score
Raw scoreFingolimodInterferon Beta 1b
Change From Screening in Paced Auditory Serial Addition Test - 3 Seconds (PASAT 3) Raw Score7.14 ± 1.246.68 ± 2.13
Statistical analysis
  • Fingolimod vs Interferon Beta 1b · ANCOVA · p = 0.8561 · Mean difference (net): 0.46 · 95% CI -4.57 to 5.49
PrimaryChange From Screening in Paced Auditory Serial Addition Test - 2 (PASAT 2) Raw Score

Paced Auditory Serial Addition Test (PASAT) for working memory (and sustained attention and information processing speed). The patient hears a series of numbers from recordings that are presented at the rate of one every 2 seconds in the second part of the test (PASAT-2). The patient was asked to add each consecutive digit to the one immediately preceding it. Sixty-one digits are presented for each part, and each part has a maximum of 60 correct answers. The total score ranged from 0 to 60. Higher values represent a better outcome.

Time frame:
Screening (-1month), 18 month
Reported as:
Least squares mean · Raw score
Change From Screening in Paced Auditory Serial Addition Test - 2 (PASAT 2) Raw Score
Raw scoreFingolimodInterferon Beta 1b
Change From Screening in Paced Auditory Serial Addition Test - 2 (PASAT 2) Raw Score4.79 ± 1.254.42 ± 2.14
Statistical analysis
  • Fingolimod vs Interferon Beta 1b · ANCOVA · p = 0.8858 · Mean difference (net): 0.37 · 95% CI -4.67 to 5.40
PrimaryChange From Screening in Selective Reminding Test - Delayed Recall (SRT-D) Raw Score

The tests SRT (Selective Reminding Test) for episodic memory (verbal learning and delayed recall). The Delayed SRT test is the total number of words recalled after a delayed period. The total score ranged from 0 to 12. Higher values represent a better outcome.

Time frame:
Screening (-1month), 18 month
Reported as:
Least squares mean · Raw score
Change From Screening in Selective Reminding Test - Delayed Recall (SRT-D) Raw Score
Raw scoreFingolimodInterferon Beta 1b
Change From Screening in Selective Reminding Test - Delayed Recall (SRT-D) Raw Score0.57 ± 0.230.39 ± 0.40
Statistical analysis
  • Fingolimod vs Interferon Beta 1b · ANCOVA · p = 0.7119 · Mean difference (net): 0.17 · 95% CI -0.76 to 1.11
PrimaryChange From Screening in Spatial Recall Test - Delayed Recall (SPART-D)

Spatial Recall Test (SPART) for visuospatial learning and delayed recall.Spatial Recall Test (10/36): The spatial recall test assesses visuospatial learning and delayed recall (10/36-D). A checkerboard with ten checkers arranged in a pattern was shown to the subject for ten seconds. The subject was then asked to reproduce the same pattern with ten checkers on an empty checkerboard. The test includes three consecutive trials. The score was the total number of correct responses for the tree trials. The total score ranged from 0 to 10. Higher values represent a better outcome.

Time frame:
Screening (-1month), 18 month
Reported as:
Least squares mean · Raw score
Change From Screening in Spatial Recall Test - Delayed Recall (SPART-D)
Raw scoreFingolimodInterferon Beta 1b
Change From Screening in Spatial Recall Test - Delayed Recall (SPART-D)0.41 ± 0.210.44 ± 0.36
Statistical analysis
  • Fingolimod vs Interferon Beta 1b · ANCOVA · p = 0.9496 · Mean difference (net): -0.03 · 95% CI -0.86 to 0.81
PrimaryChange From Screening in Word List Generation (WLG)

Word List Generation (COWAT/WLG): The COWAT assesses verbal fluency on semantic stimulus by asking the patient to produce as many words as possible belonging to a semantic category. The test assessed the verbal fluency, recorded all the possible correct word that a patients should give in 90 sec. No maximum range is available. Higher values represent a better outcome. The score was the number of correct words. The more words the patient pronounces, the better it is. We can imagine that the minimum value might be zero words, , but it is not a score scale.

Time frame:
Screening (-1month), 18 month
Reported as:
Least squares mean · Raw score
Change From Screening in Word List Generation (WLG)
Raw scoreFingolimodInterferon Beta 1b
Change From Screening in Word List Generation (WLG)0.39 ± 0.580.24 ± 0.99
Statistical analysis
  • Fingolimod vs Interferon Beta 1b · ANCOVA · p = 0.8944 · Mean difference (net): 0.16 · 95% CI -2.18 to 2.50
PrimaryChange From Screening in Delis-Kaplan Executive Function System (DKEFS) Condition 1: Free Sorting, Confirmed Correct Sort- Card Set 1+2

The Delis-Kaplan Executive Function System - Sorting Test is one of the nine tests presented in the DKEFS manual and explores the patient's executive abilities. It has a standard form (version A, administered at screening and Month-18 visit) and an alternate form (version B, administered at Month-9 visit). The standard form consists of the practice card set, card set 1 and card set 2. The alternate form consists of the same practice card set, card set 3 and card set 4. The DKFES test consisted of two testing procedures: free sorting and sort recognition. In free sorting, six scores were obtained: Confirmed Correct sorts for card sets 1 and 2 (or 3 and 4 for version B), sum of confirmed Correct Sorts. In sort recognition, a description score for card set 1 and 2 (or 3 and 4 for version B) was obtained, as well as the sum of description scores of both sets. The total score ranged from 0 to 16. Higher values represent a better outcome

Time frame:
Screening (-1month), 18 month
Reported as:
Least squares mean · Raw score
Change From Screening in Delis-Kaplan Executive Function System (DKEFS) Condition 1: Free Sorting, Confirmed Correct Sort- Card Set 1+2
Raw scoreFingolimodInterferon Beta 1b
Change From Screening in Delis-Kaplan Executive Function System (DKEFS) Condition 1: Free Sorting, Confirmed Correct Sort- Card Set 1+20.57 ± 0.310.82 ± 0.48
Statistical analysis
  • Fingolimod vs Interferon Beta 1b · ANCOVA · p = 0.6757 · Mean difference (net): -0.25 · 95% CI -1.42 to 0.92
PrimaryChange From Screening in DKEFS Condition 1: Free Sorting, Free Sorting, Description Score, Card Set 1+2

The Delis-Kaplan Executive Function System - Sorting Test is one of the nine tests presented in the DKEFS manual and explores the patient's executive abilities. It has a standard form (version A, administered at screening and Month-18 visit) and an alternate form (version B, administered at Month-9 visit). The standard form consists of the practice card set, card set 1 and card set 2. The alternate form consists of the same practice card set, card set 3 and card set 4. In free sorting, six scores were obtained: Confirmed Correct sorts for card sets 1 and 2 (or 3 and 4 for version B), sum of confirmed Correct Sorts, Free Sorting Description score for card set 1 and 2 (or 3 and 4 for version B) and sum of Free Sorting Description scores. In sort recognition, a description score for card set 1 and 2 (or 3 and 4 for version B) was obtained, as well as the sum of description scores of both sets. The total score ranged from 0 to 64. Higher values represent a better outcome

Time frame:
Screening (-1month), 18 month
Reported as:
Least squares mean · Raw score
Change From Screening in DKEFS Condition 1: Free Sorting, Free Sorting, Description Score, Card Set 1+2
Raw scoreFingolimodInterferon Beta 1b
Change From Screening in DKEFS Condition 1: Free Sorting, Free Sorting, Description Score, Card Set 1+21.52 ± 1.233.69 ± 1.92
Statistical analysis
  • Fingolimod vs Interferon Beta 1b · ANCOVA · p = 0.3585 · Mean difference (net): -2.16 · 95% CI -6.82 to 2.50
PrimaryChange From Screening in DKEFS Condition 2: Sort Recognition, Sort Recognition Description Score- Card Set 1+2

The Delis-Kaplan Executive Function System - Sorting Test is one of the nine tests presented in the DKEFS manual and explores the patient's executive abilities. It has a standard form (version A, administered at screening and Month-18 visit) and an alternate form (version B, administered at Month-9 visit). The standard form consists of the practice card set, card set 1 and card set 2. The alternate form consists of the same practice card set, card set 3 and card set 4. Free sorting and sort recognition. In free sorting, six scores were obtained: Confirmed Correct sorts for card sets 1 and 2 (or 3 and 4 for version B), sum of confirmed Correct Sorts, Free Sorting Description score for card set 1 and 2 (or 3 and 4 for version B) and sum of Free Sorting Description scores. The total score ranged from 0 to 64. Higher values represent a better outcome.

Time frame:
Screening (-1month), 18 month
Reported as:
Least squares mean · Raw score
Change From Screening in DKEFS Condition 2: Sort Recognition, Sort Recognition Description Score- Card Set 1+2
Raw scoreFingolimodInterferon Beta 1b
Change From Screening in DKEFS Condition 2: Sort Recognition, Sort Recognition Description Score- Card Set 1+22.15 ± 1.907.38 ± 2.97
Statistical analysis
  • Fingolimod vs Interferon Beta 1b · ANCOVA · p = 0.1610 · Mean difference (net): -5.24 · 95% CI -12.62 to 2.14
SecondaryChange From Screening in the Volume of Total T2 Lesions

Change in volume of total T2-weighted lesions by visit were summarized. Negative values indicate improvement (reduction in lesion volume) and positive values worsening (increase in lesion volume

Time frame:
Screening (-1 month), 18 months
Reported as:
Mean · mm^3
Change From Screening in the Volume of Total T2 Lesions
mm^3FingolimodInterferon Beta 1b
Change From Screening in the Volume of Total T2 Lesions176.25 ± 1355.31711.81 ± 1584.42
SecondaryChange From Screening in Montgomery-Asberg Depression Rating Scale (MADRS)

MADRS measures the overall severity of depressive symptoms. The MADRS had a 10-item checklist. Items are rated on a scale of 0-6, for a total numeric range of scores from 0 (depressive symptoms absent) to 60 (numerically highest level of depressive symptoms).

Time frame:
Screening (-1month), 18 month
Reported as:
Least squares mean · Raw score
Change From Screening in Montgomery-Asberg Depression Rating Scale (MADRS)
Raw scoreFingolimodInterferon Beta 1b
Change From Screening in Montgomery-Asberg Depression Rating Scale (MADRS)-0.77 ± 0.790.13 ± 1.31
SecondaryChanges in Quality of Life, by Means of the Multiple Sclerosis Quality of Life (MSQoL-54)

A 54 question measure covers 12 domains; assesses mental and physical health. The physical health composite score is a weighted average of the physical health scales, such as physical function, health perceptions, and energy. The mental health composite score is a weighted average of the mental health scales, such as overall quality of life, cognitive function, and health distress. Each domain has a range from 0 to 100 where higher means better.

Time frame:
Baseline, 18 months
Reported as:
Least squares mean · Score
Changes in Quality of Life, by Means of the Multiple Sclerosis Quality of Life (MSQoL-54)
ScoreFingolimodInterferon Beta 1b
Mental health composite score4.76 ± 2.01-2.31 ± 3.36
Physical health composite score-1.80 ± 1.41-4.75 ± 2.46
SecondaryChanges From Baseline in Fatigue Impact Scale (mFIS, Total Score and Scores of the 3 Individual Domains).

Modified Fatigue Impact Scale (mFIS) questionnaire is described at each time point to evaluate fatigue by means of usual descriptive statistics. Three domains were also defined: Physical Subscale (sum of items 4, 6, 7, 10, 13, 14, 17, 20, 21 and therefore ranging from 0 to 36), Cognitive Subscale (sum of items 1, 2, 3, 5, 11, 12, 15, 16, 18, 19 and therefore ranging from 0 to 40) and Psychosocial Subscale (sum of items 8, 9 and therefore ranging from 0 to 8). Finally, mFIS - overall score ranged from 0 to 80. The mFIS total score was computed as the sum of scores for each item. Lower values represent a better outcome.

Time frame:
Baseline, 18 months
Reported as:
Least squares mean · Score
Changes From Baseline in Fatigue Impact Scale (mFIS, Total Score and Scores of the 3 Individual Domains).
ScoreFingolimodInterferon Beta 1b
Changes From Baseline in Fatigue Impact Scale (mFIS, Total Score and Scores of the 3 Individual Domains).2.36 ± 1.686.67 ± 2.72
SecondaryChange From Screening in the Number of New T2 Lesions

New T2 lesions at a specific visit were assessed relative to the previous visit scan. The total number of lesions (visit 8 to 18 month) is calculated as the sum of the number of lesions.

Time frame:
Screening (-1month), 18 month
Reported as:
Mean · Number of new lesions
Change From Screening in the Number of New T2 Lesions
Number of new lesionsFingolimodInterferon Beta 1b
Change From Screening in the Number of New T2 Lesions1.25 ± 2.053.33 ± 4.44
SecondaryChange From Screening in the Volume of Total T1 Hypointense Lesions

Volume of hypointense post-gadolinium T1 lesion component was measured by MRI scan. Means were estimated using a Mixed-effect model with repeated measures (MMRM) by-visit interaction.

Time frame:
Screening (-1month), 18 month
Reported as:
Mean · mm^3
Change From Screening in the Volume of Total T1 Hypointense Lesions
mm^3FingolimodInterferon Beta 1b
Change From Screening in the Volume of Total T1 Hypointense Lesions391.96 ± 986.85213.93 ± 312.24
SecondaryChange From Screening in the Number of T1 Gd+ Enhancing Lesions

Total number of post-baseline Gd-enhanced lesions is calculated as a sum of all Gd-enhanced lesions seen on post-baseline scans per visit. Real (not per slice) lesions are counted in this analysis

Time frame:
Screening (-1month), 18 month
Reported as:
Mean · Number of new lesions
Change From Screening in the Number of T1 Gd+ Enhancing Lesions
Number of new lesionsFingolimodInterferon Beta 1b
Change From Screening in the Number of T1 Gd+ Enhancing Lesions-0.64 ± 1.270.59 ± 3.98
SecondaryChange From Screening in the Percentage of Brain Volume Change

Calculations of brain volume change were performed using the structural image evaluation of normalized atrophy (SIENA), software included in the Functional Magnetic Resonance Imaging of the Brain (FMRIB) software library. SIENA is a fully automated method for estimating temporal brain volume change.

Time frame:
Screening (-1month), 18 month
Reported as:
Mean · percentage of brain volume
Change From Screening in the Percentage of Brain Volume Change
percentage of brain volumeFingolimodInterferon Beta 1b
Change From Screening in the Percentage of Brain Volume Change-0.60 ± 0.83-0.96 ± 0.71
SecondaryChanges in the Environmental Status Scale Score (ESS)

The Environmental Status Scale (ESS) is used to quickly evaluate a patient for handicap. It was derived from a measure of socio-economic status. It consists of seven parameters: (1) actual work status, (2) financial and economic status, (3) personal residence or home, (4) personal assistance required, (5) transportation, (6) community services, (7) social activity. Each parameter has a single score from minimum 0 to maximum 5. ESS score is the sum of the points for all 7 parameters: minimum score: 0; maximum score: 35. The higher the score the greater the handicap

Time frame:
Baseline, 18 month
Reported as:
Mean · Score
Changes in the Environmental Status Scale Score (ESS)
ScoreFingolimodInterferon Beta 1b
Changes in the Environmental Status Scale Score (ESS)1.08 ± 3.450.91 ± 1.98

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Fingolimod 0.5 mg—9/104 (8.7%)44/104 (42.3%)
Interferon Beta 1b—1/47 (2.1%)22/47 (46.8%)
Most frequent serious events
Showing 10 of 12
Most frequent serious events
EventFingolimod 0.5 mgInterferon Beta 1b
Blood glucose abnormalInvestigations0/1041/47
Renal colicRenal and urinary disorders2/1040/47
Atrioventricular block second degreeCardiac disorders1/1040/47
BronchopneumoniaInfections and infestations1/1040/47
Urinary tract infectionInfections and infestations1/1040/47
Facial bones fractureInjury, poisoning and procedural complications1/1040/47
Head injuryInjury, poisoning and procedural complications1/1040/47
Traumatic brain injuryInjury, poisoning and procedural complications1/1040/47
Ulna fractureInjury, poisoning and procedural complications1/1040/47
EpilepsyNervous system disorders1/1040/47
Most frequent other events
Showing 10 of 11
Most frequent other events
EventFingolimod 0.5 mgInterferon Beta 1b
Influenza like illnessGeneral disorders1/1045/47
HeadacheNervous system disorders11/1044/47
Alanine aminotransferase increasedInvestigations9/1041/47
PyrexiaGeneral disorders6/1044/47
Transaminases increasedInvestigations4/1044/47
Multiple sclerosis relapseNervous system disorders2/1044/47
HypercholesterolaemiaMetabolism and nutrition disorders7/1042/47
DepressionPsychiatric disorders7/1043/47
NasopharyngitisInfections and infestations4/1043/47
Blood triglycerides increasedInvestigations0/1043/47

Baseline characteristics

Age, Continuous
Age, Continuous(Years)FingolimodInterferon Beta 1bTotal
Mean39.53 ± 9.2837.53 ± 9.2738.91 ± 9.29
Sex: Female, Male
Sex: Female, Male(Participants)FingolimodInterferon Beta 1bTotal
Female683098
Male361753
09

Study locations

26 sites
  • Novartis Investigative Site
    Alzenau, 63755, Germany
  • Novartis Investigative Site
    Bamberg, 96049, Germany
  • Novartis Investigative Site
    Leipzig, 04103, Germany
  • Novartis Investigative Site
    Würzburg, 97080, Germany
  • Novartis Investigative Site
    Ancona, AN 60126, Italy
  • Novartis Investigative Site
    Bari, BA 70124, Italy
  • Novartis Investigative Site
    Bergamo, BG 24128, Italy
  • Novartis Investigative Site
    Montichiari, BS 25018, Italy
  • Novartis Investigative Site
    Chieti, CH 66100, Italy
  • Novartis Investigative Site
    Catania, CT 95122, Italy
  • Novartis Investigative Site
    Catania, CT 95123, Italy
  • Novartis Investigative Site
    Firenze, FI 50134, Italy
  • Novartis Investigative Site
    Genova, GE 16132, Italy
  • Novartis Investigative Site
    Pozzilli, IS 86077, Italy
  • Novartis Investigative Site
    Messina, ME 98121, Italy
  • Novartis Investigative Site
    Milano, MI 20122, Italy
  • Novartis Investigative Site
    Milano, MI 20132, Italy
  • Novartis Investigative Site
    Cefalù, PA 90015, Italy
  • Novartis Investigative Site
    Pavia, PV 27100, Italy
  • Novartis Investigative Site
    Roma, RM 00133, Italy
  • Novartis Investigative Site
    Roma, RM 00161, Italy
  • Novartis Investigative Site
    Roma, RM 00179, Italy
  • Novartis Investigative Site
    Roma, RM 00189, Italy
  • Novartis Investigative Site
    Gallarate, VA 21013, Italy
  • Novartis Investigative Site
    Napoli, 80131, Italy
  • Novartis Investigative Site
    Napoli, 80138, Italy
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2011, a primary completion of Sep 2015 and a completion of Sep 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2017, 1 year 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 8, 2011
First posted
Apr 12, 2011
Start
May 2011
Primary completionActual
Sep 2015
CompletionActual
Sep 2015
Results first posted
Mar 21, 2017
Last update
Mar 21, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 21, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01333501
Responsible party
Sponsor
First posted
Apr 12, 2011
Start date
May 2011
Primary completion
Sep 2015
Completion
Sep 2015
Results posted
Mar 21, 2017
Last update
Mar 21, 2017

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fingolimod

Start the discussion